ストックスクリーナーアプリを入手
15.98
0.38%
0.06
アフターアワーズ：
15.98
前日終値:
$15.92
開ける：
$15.84
24時間の取引高:
363.44K
Relative Volume:
0.70
時価総額：
$926.47M
収益：
-
当期純損益:
$-153.16M
株価収益率:
-4.7418
EPS:
-3.37
ネットキャッシュフロー:
$-134.48M
1週間 パフォーマンス:
-5.56%
1か月 パフォーマンス:
-2.20%
6か月 パフォーマンス:
-43.63%
1年 パフォーマンス:
+61.09%
1日の値動き範囲:
$15.15
$16.00
1週間の範囲:
$15.15
$16.79
52週間の値動き範囲:
$7.64
$30.19
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-01 | 開始されました | Stifel | Buy |
| 2024-04-15 | 開始されました | William Blair | Outperform |
| 2024-02-15 | 開始されました | Wedbush | Outperform |
| 2023-06-15 | 開始されました | TD Cowen | Outperform |
| 2022-11-21 | 開始されました | BTIG Research | Buy |
| 2021-04-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | 開始されました | Evercore ISI | Outperform |
| 2021-02-02 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-02-02 | 開始されました | SVB Leerink | Outperform |
| 2021-02-01 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Cullinan Therapeutics Inc (CGEM) 最新ニュース
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference - StockTitan
Vanguard Group Inc's Strategic Acquisition in Cullinan Therapeutics Inc - GuruFocus.com
Cullinan Therapeutics to Present Preclinical Data for - GlobeNewswire
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 - StockTitan
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $31.67 - MarketBeat
FY2027 Earnings Forecast for CGEM Issued By Leerink Partnrs - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Receives New Coverage from Analysts at UBS Group - MarketBeat
Exchange Traded Concepts LLC Sells 2,961 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
SG Americas Securities LLC Sells 70,115 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
cullinan oncology, inc. Earnings dates - RTTNews
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 3.2%Here's Why - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Short Interest Update - MarketBeat
Cullinan Oncology stock gets 5% price target increase, H.C. Wainwright remains bullish after FDA approval - Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 7%Here's Why - MarketBeat
Cullinan Therapeutics' (CGEM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cullinan Therapeutics Gets FDA Approval for Lupus Treatment Study - Marketscreener.com
Cullinan Therapeutics Receives U.S. FDA Clearance of - GlobeNewswire
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus - StockTitan
How did Cullinan Therapeutics Inc (CGEM) fare last session? - US Post News
Cullinan Therapeutics Inc [CGEM] Records 200-Day SMA of $17.94 - Knox Daily
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Algert Global LLC Reduces Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
The Potential Rise in the Price of Cullinan Therapeutics Inc (CGEM) following insiders activity - Knox Daily
Metric Deep Dive: Understanding Cullinan Therapeutics Inc (CGEM) Through its Ratios - The Dwinnex
Results from Cullinan Therapeutics Inc (CGEM) show potential - US Post News
Perceptive Advisors LLC Takes Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Blue Owl Capital Holdings LP - MarketBeat
Lynx1 Capital Management LP Buys New Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
There is no doubt that Cullinan Therapeutics Inc (CGEM) ticks all the boxes. - SETE News
Deerfield Management Company L.P. Series C Increases Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market - Benzinga
Cullinan Therapeutics Inc (CGEM)’s stock price in review: A technical analysis - US Post News
Quarterly Metrics: Quick and Current Ratios for Cullinan Therapeutics Inc (CGEM) - The Dwinnex
CGEM’s Debt-to-Equity Ratio at 0.00: What It Means for Cullinan Therapeutics Inc’s Future - The InvestChronicle
Paradigm Capital Management Inc. NY Has $39.46 Million Stock Holdings in Concentrix Co. (NASDAQ:CNXC) - MarketBeat
Rhumbline Advisers Raises Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Highlights of Current Entertainment News - Devdiscourse
Four Tri-City actors cast in Willy Wonka's wacky chocolate world - The Tri-City News
Transgender Singer Xavian Wu's Journey, China's Micro Dramas, and Meryl Streep's UN Solidarity - Devdiscourse
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 9.2% - MarketBeat
Cullinan Therapeutics Files Investigational New Drug Application with FDA for CLN-978 for Treatment of Systemic Lupus Erythematosus - Lupus Foundation of America
FDA Approval Propels ZVRA To 52-week High, ADMA, CPRX, TVTX Also Reach New Peaks - Nasdaq
BTIG maintains Buy rating on Cullinan Oncology stock By Investing.com - Investing.com Australia
Cullinan Oncology maintains Buy rating from H.C. Wainwright with steady price target - Investing.com Australia
Cullinan Therapeutics (NASDAQ:CGEM) Given Outperform Rating at Wedbush - Defense World
BTIG maintains Buy rating on Cullinan Oncology stock - Investing.com
Wedbush Reaffirms "Outperform" Rating for Cullinan Therapeutics (NASDAQ:CGEM) - MarketBeat
Analysts review Cullinan Therapeutics Inc’s rating - Knox Daily
Objective long/short (CGEM) Report - Stock Traders Daily
E Fund Management Co. Ltd. Takes $1.31 Million Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Australian HREC grants clearance for Cullinan Therapeutics’ SLE treatment trial - Clinical Trials Arena
Cullinan Therapeutics Inc (CGEM) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):